$XBI $127 -0.4%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA +1.9% Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine. source
$OCGN -6.0% Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada. source
$IGMS +8.7% IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19. source
$EVAX -0.6% Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine. source
Pipeline Updates
$ALBO -1.7% New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC. source
$SBBP +12.5% Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome. source
$MIRM +5.3% Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting. source
$ZYNE -2.3% Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. source
$CMPS -0.8% COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers. source
$ATNM +4.8% Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting. source
$ACAD +3.1% NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders. source
$PDSB 0% PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors. source
$AVDL -0.8% Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021. source
$LCTX -2.1% Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®. source
$OYST -0.6% Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases. source
$EQ +3.1% Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11. source
$BHVN -0.4% Biohaven Showcases CGRP-Antagonist Franchise Data including Nurtec® ODT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society. source
$ARWR +0.4% Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia. source
$ADPT -4.1% Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients. source
$PTGX +1.0% Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera. source
$REPL -12.0% Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1. source
$TNXP 0% Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. source
$BCRX +0.4% BioCryst Launches ORLADEYO™ (berotralstat) in Germany. source
$KALA +0.9% Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx. source
$KPTI -0.1% Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets. source
$AVXL +4.1% Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions. source
$UTHR +2.1% United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis. source
$ANVS +10.3% Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021. source
$ELOX +20.8% Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents on 5/27/21. source
$XERS +18.8% Xeris Pharmaceuticals acquiring Strongbridge Biopharma plc. source
$PLX -10.5% Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease. source
$IMPL -12.5% Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society. source
$SLS -13.5% SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies. source
$ADMP +61.4% NDA for ZIMHI submitted to FDA on 6/1/21. source
Financial Updates
$CPRX -1.1% Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®. source
Posted by FS
Comments